Bora CDMO Bora CDMO

X

Find the latest Drugs in Development and Pipeline Prospector News of Millendo Therapeutics.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Millendo Therapeutics
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
110 Miller Avenue, Suite 100 Ann Arbor, MI 48104
Telephone
Telephone
734-845-9000
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

The merger will facilitate the advancement of our broad pipeline of targeted oncology programs, including TPST-1495 and TPST-1120, which are both progressing in the clinic with encouraging early signs of clinical benefit.


Lead Product(s): TPST-1495

Therapeutic Area: Oncology Product Name: TPST-1495

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Tempest Therapeutics

Deal Size: $30.0 million Upfront Cash: Undisclosed

Deal Type: Merger March 29, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

While MLE-301 was generally well-tolerated, the data do not support moving forward with its development in the target population of peri- and post-menopausal women, especially with the evolving dynamics of a highly competitive NK3R antagonist market.


Lead Product(s): MLE-301

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: MLE-301

Highest Development Status: Phase IProduct Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 05, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The single ascending dose portion of the study will be conducted in healthy male volunteers, to determine the pharmacokinetics of MLE-301 and its pharmacodynamic profile as measured by reductions of biomarkers (luteinizing hormone, testosterone).


Lead Product(s): MLE-301

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: MLE-301

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 24, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Livoletide did not achieve statistically significant improvement in primary endpoint of change in hyperphagia and food-related behaviors relative to placebo.


Lead Product(s): Livoletide

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: Phase II/ Phase IIIProduct Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 06, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY